Showing results (21-30 of 33) with videos related to
Sort By:
Pageof 4
Cancer Genetics|January 19, 2016
The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriersYael Laitman, Lital Boker-Keinan, Michal Berkenstadt, et al.Respiratory Care|July 19, 2018
The Value of Measuring Inspiratory Capacity in Subjects With Cystic FibrosisDaphna Vilozni, Adi Dagan, Moran Lavie, et al.Annals of the American Thoracic Society|May 25, 2016
Consequences of Expiratory Flow Limitation at Rest in Subjects with Cystic FibrosisDaphna Vilozni, Moran Lavie, Miryam Ofek, et al.Journal of Pediatric Gastroenterology and Nutrition|October 19, 2018
Resting Energy Expenditure in Patients With Familial Dysautonomia: A Preliminary StudyBat-El Bar Aluma, Lucy Norcliffe-Kaufmann, Ifat Sarouk, et al.World Journal of Gastroenterology|January 10, 2015
Long-term follow-up of distal intestinal obstruction syndrome in cystic fibrosisMoran Lavie, Tzipora Manovitz, Daphna Vilozni, et al.Respiratory Medicine|August 27, 2020
Phenotypic and molecular characteristics of CF patients carrying the I1234V mutationBat El Bar Aluma, Ifat Sarouk, Hanoch Senderowitz, et al.Blood Cancer Discovery|May 15, 2024
Genotoxicity Associated with Retroviral CAR Transduction of ATM-Deficient T CellsMeir Rozenbaum, Reut Fluss, Victoria Marcu-Malina, et al.The European Respiratory Journal|August 5, 2020
Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosisAnabela S Ramalho, Eva Fürstová, Annelotte M Vonk, et al.Respiratory Medicine|September 27, 2017
Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experienceAdi Dagan, Malena Cohen-Cymberknoh, Michal Shteinberg, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 18, 2023
Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutationIdo Sadras, Eitan Kerem, Galit Livnat, et al.Pageof 4